A data manager for a European organisation of doctors

The EPSSG, the European association of paediatric oncologists specialised in soft tissue sarcoma, recently completed a large-scale clinical trial on rhabdomyosarcomas. That trial, which started in 2005, recently included its last patients in December 2016 and allowed the collection of molecular, genetic and clinical data from 2 000 patients.

KickCancer wants to support the EPSSG to have those data analysed by funding the salary of a data manager for 3 years. The in-depth analysis of those data will result in the validation of a new risk assessment and classification method, which would be uniform across the world. This new classification will contribute to an improved treatment of the patients according to their risk group.

First results: two subgroups of patients have already changed risk category. Specifically, in the new treatment protocol, a first category of children was transferred from the “high risk” to the “standard” risk group, which justifies the use of lighter treatments in the hope of reducing the long-term side effects caused by the treatments. On the other hand, a second category of patients was transferred to a higher risk group and will receive a heavier treatment in the hope of improving their survival chances.

Status and next steps: there will be two interim reports published in April 2019 and 2020; a final report on the projects is expected in the Spring of 2021.

A data manager for a European organisation of doctors

  • Financed: 93 000 euros
    More than 85% of your donations go to financing research and supporting our advocacy work, less than 15% go to administration.
  • Duration: 3 years
  • Countries: Europe
  • Disease: Rhabdomyosarcoma
  • Status: Finished